volume 41, pages 1669–1678 (2023)Cite this article
1381 Accesses
45 Altmetric
Nature Biotechnology’s annual survey highlights academic start ups that are, among other things, correcting misfolded or disordered proteins, creating second-generation GPCR agonists, building a new gene delivery platform and mining cancer genomes for novel targets.
As in previous years of our survey, we focus on R&D-intensive startups spun out from academic institutions (Table 1). These were first identified as having raised a series A financing in 2021. Our editors then assessed publicly available information about each firm’s research to select those that appear below. (Some firms were selected but not included because they were still in ‘stealth mode’ or declined to be interviewed.)
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
214,86 € per year
only 17,91 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
About this article
Cite this article
Eisenstein, M., Schmidt, C. & DeFrancesco, L. Nature Biotechnology’s academic spinouts 2022.
Nat Biotechnol 41, 1669–1678 (2023). https://doi.org/10.1038/s41587-023-02023-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-02023-z